University General Hospital Of Ioannina
- Address
- lock Available on a paid plan
University General Hospital Of Ioannina - Clinical Research Center
The University General Hospital Of Ioannina stands as a leading clinical research institution with extensive expertise across a diverse range of therapeutic areas. The center demonstrates particular strength in hematological malignancies, conducting multiple Phase 2 and 3 trials in chronic lymphocytic leukemia, multiple myeloma, and mantle cell lymphoma, utilizing novel targeted therapies and immunotherapies including BTK inhibitors, bispecific antibodies, and antibody-drug conjugates.
- Oncology and hematology research, including advanced lymphomas, multiple myeloma, and solid tumors (lung cancer, breast cancer, urothelial cancer)
- Respiratory medicine trials focusing on COPD, asthma, idiopathic pulmonary fibrosis, and bronchiectasis
- Cardiovascular and renal disease studies, including chronic kidney disease, heart failure prevention, and cardiovascular outcomes
- Autoimmune and inflammatory conditions, including multiple sclerosis, Sjögren's syndrome, and chronic inflammatory demyelinating polyneuropathy
The research center also maintains active programs in metabolic disorders such as dyslipidemia and familial hypercholesterolemia, infectious diseases including candidemia and community-acquired pneumonia, and rare conditions including sickle cell disease and myelofibrosis. The hospital's broad participation in international multicenter trials demonstrates its commitment to advancing therapeutic options across the full spectrum of complex medical conditions, from neurodegenerative disorders to dermatologic diseases like lichen simplex chronicus.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 21 therapeutic areas and 15 of 274 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 254 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 45 by active trials.
- 1AstraZeneca AB14active
lock +44 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB21trials
lock +29 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in University General Hospital Of Ioannina
lock Showing 1 of 174 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis (IC-MPGN) | Novartis Pharma AG | Phase III | Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 274 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 12 | Unknown | 2020-09-28 | 2026-06-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.